Obesity is now recognized as a major risk factor for the development of several types of cancer, significantly influencing diagnosis, treatment response and clinical outcomes. Metabolic, inflammatory and hormonal alterations associated with excess body weight play a key role in carcinogenesis and tumor progression.
At the same time, advances in bariatric surgery and the introduction of new metabolic pharmacological therapies are reshaping prevention strategies and the clinical management of obese patients, including those with oncological conditions.
The Bariatric & Oncology Summit is designed to explore the complex interplay between obesity and cancer through a multidisciplinary perspective, addressing clinical, diagnostic and therapeutic challenges. The course brings together experts in bariatric and oncologic surgery, oncology, endoscopy, nutrition and anesthesiology to share the latest evidence and best practices.
The primary aim of the Summit is to improve the management of obese and obese-oncological patients by promoting integrated care pathways, optimizing prevention and treatment strategies, and advancing innovative approaches to screening and personalized medicine.